KYTHERA Biopharma Priced, Nasdaq: KYTH
Commercializing an injectable treatment for double chins with Bayer.
Industry: Health Care
First Day Return: +23.7%
KYTH
Commercializing an injectable treatment for double chins with Bayer.
| IPO Data | |
|---|---|
| IPO Date | 10/10/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $70 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Calabasas, CA, United States |
| Founded | 2005 |
| Employees at IPO | 39 |
| Website www.kytherabiopharma.com | |
IPO News for KYTHERA Biopharma
KYTHERA Biopharma (KYTH) Performance
